Expression of a soluble transforming growth factor-β (TGFβ) receptor reduces tumorigenicity by regulating natural killer (NK) cell activity against 9L gliosarcoma in vivo

Timothy F Witham, Lorissa Villa, Tianbing Yang, Ian F. Pollack, Hideho Okada, Paul D. Robbins, William H. Chambers

Research output: Contribution to journalArticle

Abstract

Immunotherapy of gliomas has been forwarded as an attractive alternative to standard therapeutic modalities. Numerous observations indicate some therapeutic efficacy with this approach, but it is not curative in most reports. It is well established that gliomas suppress immune reactivity via a number of mechanisms, including expression CD95 ligand (CD95L), which induces apoptosis of immune effector cells, and secretion of immunosuppressive factors such as transforming growth factor-beta (TGFβ). It has been hypothesized that abrogation of production or function of TGFβ would improve immune reactivity to gliomas. To investigate this in a fashion that is translatable into clinical practice, we utilized a retroviral vector encoding a truncated, soluble form of the Type II receptor for TGFβ (TFGβsr) and expressed it in the rat 9L gliosarcoma line (9L-TGFβsr). We then determined whether expression of TGFβsr affected in vitro sensitivity of 9L to lysis by immune effector cells, whether expression of TGFβsr affected tumorigenesis of 9L in vivo, and whether TGFβsr affected expression of immunity to 9L. In these experiments, we determined that 9L-TGFβsr was more susceptible than sham transfected 9L (9L-neo) to lysis by natural killer (NK) cells. We also determined that subcutaneously implanted 9L-TGFβsr was less tumorigenic than 9L-neo in syngeneic rats. Similarly, survival was extended by ∼40% in rats given intracranial 9L-TGFβsr compared to 9L-neo. Finally, we determined that elimination of CD161+ cells resulted in comparable growth of 9L-neo and 9L-TGFβsr in vivo, indicating that NK or NK-like cells were responsible for the anti-tumor effects in this model.

Original languageEnglish (US)
Pages (from-to)63-69
Number of pages7
JournalJournal of Neuro-Oncology
Volume64
Issue number1-2
DOIs
StatePublished - Aug 2003
Externally publishedYes

Fingerprint

Gliosarcoma
Growth Factor Receptors
Transforming Growth Factors
Glioma
Natural Killer Cells
Fas Ligand Protein
Immunosuppressive Agents
Transforming Growth Factor beta
Immunotherapy
Immunity
Carcinogenesis
Apoptosis
Therapeutics
Growth
Neoplasms

Keywords

  • Gliomas
  • Immunotherapy
  • NK
  • TGFβ

ASJC Scopus subject areas

  • Clinical Neurology
  • Cancer Research
  • Oncology
  • Neuroscience(all)

Cite this

Expression of a soluble transforming growth factor-β (TGFβ) receptor reduces tumorigenicity by regulating natural killer (NK) cell activity against 9L gliosarcoma in vivo. / Witham, Timothy F; Villa, Lorissa; Yang, Tianbing; Pollack, Ian F.; Okada, Hideho; Robbins, Paul D.; Chambers, William H.

In: Journal of Neuro-Oncology, Vol. 64, No. 1-2, 08.2003, p. 63-69.

Research output: Contribution to journalArticle

Witham, Timothy F ; Villa, Lorissa ; Yang, Tianbing ; Pollack, Ian F. ; Okada, Hideho ; Robbins, Paul D. ; Chambers, William H. / Expression of a soluble transforming growth factor-β (TGFβ) receptor reduces tumorigenicity by regulating natural killer (NK) cell activity against 9L gliosarcoma in vivo. In: Journal of Neuro-Oncology. 2003 ; Vol. 64, No. 1-2. pp. 63-69.
@article{56a9a6ef90294be4888809dcc057e9cf,
title = "Expression of a soluble transforming growth factor-β (TGFβ) receptor reduces tumorigenicity by regulating natural killer (NK) cell activity against 9L gliosarcoma in vivo",
abstract = "Immunotherapy of gliomas has been forwarded as an attractive alternative to standard therapeutic modalities. Numerous observations indicate some therapeutic efficacy with this approach, but it is not curative in most reports. It is well established that gliomas suppress immune reactivity via a number of mechanisms, including expression CD95 ligand (CD95L), which induces apoptosis of immune effector cells, and secretion of immunosuppressive factors such as transforming growth factor-beta (TGFβ). It has been hypothesized that abrogation of production or function of TGFβ would improve immune reactivity to gliomas. To investigate this in a fashion that is translatable into clinical practice, we utilized a retroviral vector encoding a truncated, soluble form of the Type II receptor for TGFβ (TFGβsr) and expressed it in the rat 9L gliosarcoma line (9L-TGFβsr). We then determined whether expression of TGFβsr affected in vitro sensitivity of 9L to lysis by immune effector cells, whether expression of TGFβsr affected tumorigenesis of 9L in vivo, and whether TGFβsr affected expression of immunity to 9L. In these experiments, we determined that 9L-TGFβsr was more susceptible than sham transfected 9L (9L-neo) to lysis by natural killer (NK) cells. We also determined that subcutaneously implanted 9L-TGFβsr was less tumorigenic than 9L-neo in syngeneic rats. Similarly, survival was extended by ∼40{\%} in rats given intracranial 9L-TGFβsr compared to 9L-neo. Finally, we determined that elimination of CD161+ cells resulted in comparable growth of 9L-neo and 9L-TGFβsr in vivo, indicating that NK or NK-like cells were responsible for the anti-tumor effects in this model.",
keywords = "Gliomas, Immunotherapy, NK, TGFβ",
author = "Witham, {Timothy F} and Lorissa Villa and Tianbing Yang and Pollack, {Ian F.} and Hideho Okada and Robbins, {Paul D.} and Chambers, {William H.}",
year = "2003",
month = "8",
doi = "10.1023/A:1024938026553",
language = "English (US)",
volume = "64",
pages = "63--69",
journal = "Journal of Neuro-Oncology",
issn = "0167-594X",
publisher = "Kluwer Academic Publishers",
number = "1-2",

}

TY - JOUR

T1 - Expression of a soluble transforming growth factor-β (TGFβ) receptor reduces tumorigenicity by regulating natural killer (NK) cell activity against 9L gliosarcoma in vivo

AU - Witham, Timothy F

AU - Villa, Lorissa

AU - Yang, Tianbing

AU - Pollack, Ian F.

AU - Okada, Hideho

AU - Robbins, Paul D.

AU - Chambers, William H.

PY - 2003/8

Y1 - 2003/8

N2 - Immunotherapy of gliomas has been forwarded as an attractive alternative to standard therapeutic modalities. Numerous observations indicate some therapeutic efficacy with this approach, but it is not curative in most reports. It is well established that gliomas suppress immune reactivity via a number of mechanisms, including expression CD95 ligand (CD95L), which induces apoptosis of immune effector cells, and secretion of immunosuppressive factors such as transforming growth factor-beta (TGFβ). It has been hypothesized that abrogation of production or function of TGFβ would improve immune reactivity to gliomas. To investigate this in a fashion that is translatable into clinical practice, we utilized a retroviral vector encoding a truncated, soluble form of the Type II receptor for TGFβ (TFGβsr) and expressed it in the rat 9L gliosarcoma line (9L-TGFβsr). We then determined whether expression of TGFβsr affected in vitro sensitivity of 9L to lysis by immune effector cells, whether expression of TGFβsr affected tumorigenesis of 9L in vivo, and whether TGFβsr affected expression of immunity to 9L. In these experiments, we determined that 9L-TGFβsr was more susceptible than sham transfected 9L (9L-neo) to lysis by natural killer (NK) cells. We also determined that subcutaneously implanted 9L-TGFβsr was less tumorigenic than 9L-neo in syngeneic rats. Similarly, survival was extended by ∼40% in rats given intracranial 9L-TGFβsr compared to 9L-neo. Finally, we determined that elimination of CD161+ cells resulted in comparable growth of 9L-neo and 9L-TGFβsr in vivo, indicating that NK or NK-like cells were responsible for the anti-tumor effects in this model.

AB - Immunotherapy of gliomas has been forwarded as an attractive alternative to standard therapeutic modalities. Numerous observations indicate some therapeutic efficacy with this approach, but it is not curative in most reports. It is well established that gliomas suppress immune reactivity via a number of mechanisms, including expression CD95 ligand (CD95L), which induces apoptosis of immune effector cells, and secretion of immunosuppressive factors such as transforming growth factor-beta (TGFβ). It has been hypothesized that abrogation of production or function of TGFβ would improve immune reactivity to gliomas. To investigate this in a fashion that is translatable into clinical practice, we utilized a retroviral vector encoding a truncated, soluble form of the Type II receptor for TGFβ (TFGβsr) and expressed it in the rat 9L gliosarcoma line (9L-TGFβsr). We then determined whether expression of TGFβsr affected in vitro sensitivity of 9L to lysis by immune effector cells, whether expression of TGFβsr affected tumorigenesis of 9L in vivo, and whether TGFβsr affected expression of immunity to 9L. In these experiments, we determined that 9L-TGFβsr was more susceptible than sham transfected 9L (9L-neo) to lysis by natural killer (NK) cells. We also determined that subcutaneously implanted 9L-TGFβsr was less tumorigenic than 9L-neo in syngeneic rats. Similarly, survival was extended by ∼40% in rats given intracranial 9L-TGFβsr compared to 9L-neo. Finally, we determined that elimination of CD161+ cells resulted in comparable growth of 9L-neo and 9L-TGFβsr in vivo, indicating that NK or NK-like cells were responsible for the anti-tumor effects in this model.

KW - Gliomas

KW - Immunotherapy

KW - NK

KW - TGFβ

UR - http://www.scopus.com/inward/record.url?scp=0043065313&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0043065313&partnerID=8YFLogxK

U2 - 10.1023/A:1024938026553

DO - 10.1023/A:1024938026553

M3 - Article

C2 - 12952287

AN - SCOPUS:0043065313

VL - 64

SP - 63

EP - 69

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

IS - 1-2

ER -